nivolumab (Opdivo)

following a full submission assessed under the end of life process

nivolumab (Opdivo®) is accepted for use within NHS Scotland.

Indication under review: Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

Nivolumab, compared with a standard second-line chemotherapy, significantly increased overall survival in patients with locally advanced or metastatic squamous NSCLC who had received previous therapy including platinum-based doublet chemotherapy.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of nivolumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.